Home » Stocks » Aileron Therapeutics

Aileron Therapeutics, Inc. (ALRN)

Stock Price: $1.16 USD 0.03 (2.65%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 44.29M
Revenue (ttm) n/a
Net Income (ttm) -28.90M
Shares Out 38.18M
EPS (ttm) -1.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $1.16
Previous Close $1.13
Change ($) 0.03
Change (%) 2.65%
Day's Open 1.14
Day's Range 1.10 - 1.18
Day's Volume 338,564
52-Week Range 0.25 - 1.99

More Stats

Market Cap 44.29M
Enterprise Value 36.49M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.18M
Float 15.39M
EPS (basic) -1.03
EPS (diluted) -1.04
FCF / Share -0.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 955,829
Short Ratio 0.53
Short % of Float 3.01%
Beta 3.73
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.69
Revenue n/a
Operating Income -29.45M
Net Income -28.90M
Free Cash Flow -24.60M
Net Cash 7.79M
Net Cash / Share 0.20
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -86.27%
ROE -255.61%
ROIC -137.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.00*
(331.03% upside)
Low
2.00
Current: 1.16
High
8.00
Target: 5.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-29.96-31.90-23.01-18.17-12.89
Net Income-29.37-31.55-22.60-18.12-12.88
Shares Outstanding24.5414.747.440.430.40
Earnings Per Share-1.20-2.14-3.04-42.35-32.31
Operating Cash Flow-26.47-27.93-20.53-15.01-11.71
Capital Expenditures-0.15-4.42-0.14--0.09
Free Cash Flow-26.63-32.35-20.67-15.01-11.80
Cash & Equivalents18.3020.7250.8420.803.83
Total Debt5.035.34---
Net Cash / Debt13.2715.3850.8420.803.83
Assets26.4730.3152.6922.025.94
Liabilities10.4310.714.894.082.58
Book Value16.0519.6047.80-112-94.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aileron Therapeutics, Inc.
Country United States
Employees 13
CEO Manuel C. Aivado

Stock Information

Ticker Symbol ALRN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALRN
IPO Date June 29, 2017

Description

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.